Boston-based startup Helios has emerged from stealth with a focus on using artificial intelligence to predict disease risks from a single drop of blood. The company, which is backed by Y Combinator, has secured $2.3 million in seed funding from investors including Formation VC and various angel investors.
The technology developed by Helios analyzes over 1,000 proteins in a blood sample to identify biological signals linked to aging and conditions such as Alzheimer’s disease, heart failure, and blood cancers. The process utilizes a needle-free collection device that users mail to the company’s laboratory in Boston for analysis.
Helios plans to launch its testing service in early 2027, starting with concierge physicians and longevity clinics. The expected cost for clinical buyers ranges from $250 to $600 per test, with plans to offer the service directly to consumers later that same year.
The startup was founded by Omar Abudayyeh, Jonathan Gootenberg, and Yousef Badran. The founders previously worked on CRISPR diagnostics research at Harvard and MIT and helped establish Sherlock Biosciences. The company also intends to integrate medical records and wearable device data into its AI models.




